Educational Grants

Collegium Pharmaceutical is committed to advancing education in serious and complex medical conditions. We support high-quality independent medical education programs that reflect that commitment and help close the gap between scientific evidence and clinical practice.

Collegium respects the independence of educational grant recipients and does not offer or provide any support in the creation or administration of an educational program.

Medical education grants requests can be submitted to: EducationalGrantReviewCommittee@collegiumpharma.com.

Collegium is currently accepting medical education grant requests on the following educational and scientific topics of interest:

Attention Deficit Hyperactivity Disorder (ADHD) Education

  • Support education to improve HCP understanding of ADHD pharmacotherapy, including the clinical profiles and mechanisms of extended-release, delayed-release, and prodrug stimulant formulations
  • Support education on evidence-based treatment selection and optimization strategies, including dose titration, switching considerations, management of tolerability issues, and approaches to addressing partial response or inadequate duration of coverage
  • Support education on individualized ADHD treatment planning that considers ADHD symptom timing, duration of effect, patient lifestyle, caregiver burden, and functional needs across the day
  • Support education to increase awareness of the clinical and functional consequences of suboptimal ADHD symptom control, including impacts on academic/work performance, emotional regulation, and quality of life

Investigator-Initiated Studies

Collegium’s support for Investigator-Initiated Studies reflects our commitment to advancing real-world understanding of our medicines and the conditions they are designed to treat, particularly in areas where patients have conditions that have gone underserved.

For more information regarding Investigator-Initiated Studies (IIS), please contact us at: IISProgram@collegiumpharma.com.

Areas of Interest:

Attention Deficit Hyperactivity Disorder (ADHD)

Delayed-Release/Extended-Release Methylphenidate (DR/ER-MPH)

  • Research evaluating treatment optimization strategies with DR/ER-MPH, including dose titration, switching considerations, adherence, tolerability, and management of partial response or inadequate duration of coverage
  • Research investigating ADHD symptom control and functional outcomes associated with DR/ER-MPH, including early morning, school/workday, and evening functioning
  • Research that further informs the appropriate clinical use of DR/ER-MPH in ADHD, including use in special populations and patients with comorbid conditions
  • Research evaluating the efficacy, safety, and functional outcomes of DR/ER-MPH in patients with ADHD and comorbidities, including but not limited to autism spectrum disorder, anxiety, depression, bipolar disorder, and sleep-related challenges
  • Research evaluating the role of DR/ER-MPH in addressing individualized ADHD treatment needs, including symptom timing, duration of effect, and functional impairment across the day
  • Research evaluating the abuse deterrent potential associated with DR/ER-MPH

Serdexmethylphenidate/Dexmethylphenidate (SDX/d-MPH)

  • Research evaluating treatment optimization strategies with SDX/d-MPH, including dose titration, switching considerations, adherence, tolerability, and management of partial response or inadequate duration of coverage
  • Research investigating ADHD symptom control and functional outcomes associated with SDX/d-MPH, including early morning, school/workday, and evening functioning
  • Research that further informs the appropriate clinical use of SDX/d-MPH in ADHD, including use in special populations and patients with comorbid conditions
  • Research evaluating the efficacy, safety, and functional outcomes of SDX/d-MPH in patients with ADHD and comorbidities, including but not limited to autism spectrum disorder, anxiety, depression, bipolar disorder, and sleep-related challenges
  • Research evaluating the role of SDX/d-MPH in addressing individualized ADHD treatment needs, including symptom timing, duration of effect, and functional impairment across the day
  • Research evaluating the abuse deterrent potential associated with SDX/d-MPH
  • Research that investigates the use of SDX/d-MPH in non-ADHD therapeutic areas where there is a strong scientific rationale